These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 35441911

  • 1. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 2. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M, An Z, Tang Q, Ma Y, Yan J, Chen S, Wang Y.
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [Abstract] [Full Text] [Related]

  • 3. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 4. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D, Xu X, Wen J, Zhang C, Fan M.
    Lung Cancer; 2021 Oct 07; 160():32-35. PubMed ID: 34391065
    [Abstract] [Full Text] [Related]

  • 5. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q, Xu H, Liu Y, Zhang W, Sun C, Hu M, Zhu Y, Tan S, Xu X, Wang S, Liu L.
    Lung Cancer; 2021 Dec 07; 162():86-89. PubMed ID: 34763158
    [Abstract] [Full Text] [Related]

  • 6. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X, Yang X, Tan Y, Duan Q, He M.
    Invest New Drugs; 2022 Oct 07; 40(5):1160-1163. PubMed ID: 35608716
    [Abstract] [Full Text] [Related]

  • 7. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F, Gao F, Wu H, Lu J, Xu Y, Zhao Y.
    Thorac Cancer; 2022 Apr 07; 13(7):1088-1090. PubMed ID: 35212154
    [Abstract] [Full Text] [Related]

  • 8. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 9. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J, Wang W, Lin J, Chen R, Cao Y.
    J Cell Mol Med; 2022 Oct 08; 26(20):5326-5329. PubMed ID: 36102237
    [Abstract] [Full Text] [Related]

  • 10. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
    Tang Q, Li T, Ren F, Li X, Cao W, Yu H, Mao F, Cao C, Zu L, Xu S.
    J Natl Compr Canc Netw; 2024 Feb 15; 22(2):. PubMed ID: 38364363
    [Abstract] [Full Text] [Related]

  • 11. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L, Hou F, Liu Y, Li W, Zhang H.
    J Natl Compr Canc Netw; 2021 Nov 11; 20(1):2-6. PubMed ID: 34763318
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q, Guo T, Zhou Y, Sun L, Meng M, Ma L, Wang X.
    Thorac Cancer; 2022 Feb 11; 13(4):637-642. PubMed ID: 34964276
    [Abstract] [Full Text] [Related]

  • 13. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul 11; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 14. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
    Dai S, Liu XQ, Wu Q, Du CM, Liu Q, Xue YY, Luo F, Li Y.
    Lung Cancer; 2023 Jan 11; 175():121-124. PubMed ID: 36495785
    [Abstract] [Full Text] [Related]

  • 15. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y, Zhang X, Jiang Q, Wang B, Wang Y, Junrong Y.
    Lung Cancer; 2020 Aug 11; 146():370-372. PubMed ID: 32527613
    [Abstract] [Full Text] [Related]

  • 16. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug 11; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

  • 17. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z, Wu Q, Li W, Li P, Huang L, Wang T, Zhou Q.
    Lung Cancer; 2023 Dec 11; 186():107386. PubMed ID: 37922771
    [Abstract] [Full Text] [Related]

  • 18. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul 11; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 19. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
    Wang Y, Shen S, Hu P, Geng D, Zheng R, Li X.
    Cancer Med; 2022 Dec 11; 11(23):4491-4500. PubMed ID: 35616090
    [Abstract] [Full Text] [Related]

  • 20. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H, Liu Y, Wang W, Tang Y, Tian P, Li W.
    Ann Palliat Med; 2021 Jul 11; 10(7):8352-8357. PubMed ID: 33832282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.